Journal
NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/ncomms12231
Keywords
-
Categories
Funding
- Mayo Clinic relief award [CA190272RELIEF]
- Mayo Center for Individualized Medicine Biomarker Discover programme lung cancer group fund
- Mayo Clinic Cancer Center Fraternal Order of Eagles Cancer Research Fund
- NCI R21 award [CA184817]
- NCI R01 award [CA080127, CA084354]
- NCI [K08 CA151661, R21 CA153017]
- MD Anderson Cancer Center Physician Scientist Award
- NIH [CA125123]
- CPRIT grant [RP120713-C2]
Ask authors/readers for more resources
The Zinc-finger E-box-binding Homeobox-1 (ZEB1) is a transcription factor that promotes epithelial-mesenchymal transition (EMT) and acts as an oncogene in KRAS-mutated lung cancer models. Here we report that ZEB1 exerts the opposite effect in EGFR-mutated lung cancer cells, where it suppresses growth by increasing microRNA-200 targets to antagonize ERBB3, a driver of mutant EGFR-dependent cell growth. Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3. Furthermore, we find that EGFR inhibitor treatment, which inhibits the growth of EGFR-mutated cells, induces ZEB1. Despite its growth-inhibiting effect, EGFR inhibitor-induced ZEB1 strongly promotes EMT-dependent resistance to EGFR inhibitors partially through NOTCH1, suggesting a multifunctional role for NOTCH1 in EGFR-mutated cells. These results support a previously unrecognized genetic cell context-dependent role for ZEB1 and suggest that NOTCH1 may be a useful target for treating resistance to EGFR inhibitors, especially EMT-driven resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available